Prevail Therapeutics

📍 New York, United States🗓 Founded 2017👥 84 employees💰 Last funded Mar 2019
Biotechnology🌐 prevailtherapeutics.com
Website LinkedIn
At Prevail Therapeutics, we are developing novel gene therapies that target the root genetic causes of Parkinson’s disease and other neurodegenerative disorders. Our mission is to translate recent advances in human genetics and gene therapy technology into medicines that slow or stop the neurodegenerative process. Our programs utilize a precision medicine approach targeting patient populations with urgent unmet needs, where there are currently no available therapies that modify the progressive course of their disorders. Prevail was formed in 2017 and we are building a team of dedicated, creative and talented individuals who share our passion for serving patients with neurodegenerative diseases. We pride ourselves on following great science, and we value collaboration, integrity and agility. We are based in the Alexandria Center for Life Science in New York City. Prevail Therapeutics was acquired by Eli Lilly and Company in January of 2021, and is now a wholly owned subsidiary of Eli Lilly. For information please visit the www.lilly.com website.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Prevail Therapeutics?
Prevail Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Prevail Therapeutics last raise funding?
The most recent investment in Prevail Therapeutics recorded on gritt.io was in March 2019.
When was Prevail Therapeutics founded?
Prevail Therapeutics was founded in 2017.
What industry is Prevail Therapeutics in?
Prevail Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Prevail Therapeutics based?
Prevail Therapeutics is headquartered in New York, United States.